Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zr-89-girentuximab PET/CT in ccRCC
NCT02883153Phase 3Completed
- Sponsor
- Radboud University Medical Center
- Start
- Dec 2015
- Primary completion
- Jun 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of 89Zr-DFO-girentuximab in renal cell carcinoma (RCC), sponsored by Radboud University Medical Center. Started Dec 2015; status: completed.
02
Drugs
89Zr-DFO-girentuximab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02883153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02883153.